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Background: Recently, attenuation of anti-inﬂammatory and increase of pro-inﬂammatory mediators was
demonstrated in individuals with Down syndrome (DS) in comparison with euploid patients during peri-
odontal disease (PD), suggesting a shift to a more aggressive inﬂammation in DS.
Aim: To determine the inﬂuence of DS in the modulation of interferons (IFNs) signaling pathway in PD.
Materials and methods: Clinical periodontal assessment was performed and gingival tissue samples
obtained from a total of 51 subjects, including 19 DS individuals with PD, 20 euploid individuals with
PD and 12 euploid individuals without PD. Expression levels of interferon-gamma (IFNG) and interferon-
alpha (IFNA), and their receptors IFNGR1, IFNGR2, IFNAR1 and IFNAR2, the signaling intermediates Janus
kinase 1 (JAK1), signal transducer and activator of transcription 1 (STAT1) and interferon regulatory factor
1 (IRF1) were determined using real time quantitative polymerase chain reaction (qPCR).
Results: Clinical signs of periodontal disease were markedly more severe in DS and euploid patients with
PD in comparison to euploid and periodontally healthy patients. There was no difference on mRNA levels
of IFNA, IFNG, INFGR2, IFNAR1 and IFNAR2 between DS and euploid individuals, even though some of these
genes are located on chromosome 21. STAT1 and IRF1mRNA levels were signiﬁcantly lower in DS patients
in comparison with euploid individuals with PD. In euploid individuals, PD was associated with an
increased expression of IFNGR1, IFNGR2, IFNAR1, STAT1 and IRF1.
Conclusions: Reduced expression of STAT1 and IRF1 genes indicate an impaired activation of IFNs signal-
ing in individuals with DS and PD. Expression of IFNA, IFNG and IFN receptors was not altered in DS
patients, indicating that indirect mechanisms are involved in the reduced activation of IFN signaling.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Down syndrome (DS), or trisomy 21, is a very frequent autoso-
mal chromosomal disorder caused by an error in cell division that
results in the presence of all or part of an extra chromosome 21 [1].
The overexpression of speciﬁc genes found on chromosome 21
cause a complex condition with more than 30 clinical features
[2,3]. Many studies have reported that DS individuals have an in-rphology, School of Dentistry
maitá, 1680, Centro, CP. 331,
5 16 3301 6504; fax: +55 16
Caminaga).
er OA license.creased prevalence of periodontal disease (PD) compared with
otherwise chromosomally normal (euploid), age-matched control
and other mentally handicapped patients of similar age distribu-
tion [4–7]. So, the high susceptibility to PD was not only related
to poor oral hygiene, but also associated with the congenital disor-
der [8,9] in DS individuals [8–10].
Periodontal diseases are characterized by a destruction of the
periodontium and eventually tooth loss [11] and are caused by lo-
cal etiologic factors, especially the dental bioﬁlm, but systemic dis-
orders may reduce or change the resistance or the host response to
this factor [12]. Additionally, signiﬁcant correlations were found
between the prevalence of bone loss and both the age and the
neutrophil chemotactic index in DS individuals. The rate of the
periodontal destruction seems to depend on the severity and
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hygiene [13]. Abnormalities in the immune response are important
contributing factors to the high incidence of PD in individuals with
DS, such as production of oxidative radicals [14,15], decreased che-
motaxis and phagocytosis of polymorphonuclear leukocytes
(PMNs) [15,16], and reduced T lymphocyte counts and immature
T lymphocytes [13,17]. This impaired host response characterized
by disturbances of the T and B lymphocyte subsets, leads to dysreg-
ulation of cytokines, chemokines and prostaglandins [18]. Re-
cently, our research group demonstrated an attenuation of IL10
and SOCS3 gene expression with a simultaneous increase of STAT3
mRNA levels in individuals with DS during periodontitis in com-
parison with euploid individuals with PD [19]. These results indi-
cated and inhibition of endogenous negative regulators of
inﬂammation in DS patients during PD.
A plethora of cytokines has been found in diseased human peri-
odontal tissues, including interferons (IFNs) [12,20–22]. Interfer-
ons are a large family of cytokines with broad function, such as
antiviral, antitumor, antiproliferative, and immunomodulatory ef-
fects [23,24]. Interferon-alpha, also known as type I IFN, is coded
by the IFNA gene and is produced by ﬁbroblasts or type I helper
T cells (Th1) upon stimulation by viral or bacterial infections, as
periodontopathogenic bacteria [25–29]. The type II IFN is known
as interferon-gamma (coded by the IFNG gene) and is a more po-
tent immunomodulator than type I IFN [30]. IFN-c acts on macro-
phage activation [31], modulation of leukocyte adhesion by
stimulating intercellular adhesion molecule-1 (ICAM-1) expression
[32], and upregulates monocytic response to bacterial lipopolysac-
charide (LPS), resulting in secretion of proinﬂammatory molecules,
such as prostaglandin E2 (PGE2), Interleukin-1b (IL-1b) and tumor
necrosis factor-a (TNF-a) [33]. All of them play important roles
in periodontal tissue destruction including alveolar bone loss
[21,22,34–36]. The biological effects of IFNs are mediated by their
receptors on the cell surface. Therefore, interferons receptors’ are
important in the inﬂammatory processes. Whereas the IFNs binds
to their receptors, the mechanisms by which signal transduction
occurs that trigger speciﬁc cellular responses are mediated by
phosphorylation of Janus kinase (JAK) enzyme associated with
the IFN receptors and transcription factors STAT (Signal Transducer
and Activator of Transcription) [23,37,38]. Upon binding of the IFN-
c and IFN-a to their speciﬁc receptors, the receptor undergoes olig-
omerization, with phosphorylation of JAKs associated with the
cytoplasmic tails of these receptors. This provides a docking site
and subsequent phosphorylation of the transcription factor STATs
(Signal Transducers and Activators of Transcription) [23,37,38].
IFN-c signals induce formation of phosphorylated STAT-1 homodi-
mers, which are translocated to the nucleus, where they activate
transcription of IFN-stimulated genes (ISGs) which contain a un-
ique element called IFN-c activation site (GAS). IFN-a induces
the formation of heterodimers STAT-1/STAT-2 which are also
translocated to the nucleus and activate promoter regions of ISGs
called IFN-stimulated response element (ISRE) [39].
In addition to STATs, another set of transcription factors acti-
vated downstream of IFN receptor signaling are the IFN regulatory
factors (IRFs). This family of transcription factor plays a critical role
in antiviral defense, immune response, cell growth regulation and
apoptosis [40,41].
Interestingly, in the long arm of chromosome 21 there is a clus-
ter of genes composed by the Interleukin 10 receptor beta (IL10RB),
IFNGR2, IFN-alpha receptor 1 (IFNAR1) and the IFNAR2 gene, ori-
ented in tandem [24,42]. In addition, considering the importance
of IFNs in the immune response, some studies assessed the inﬂu-
ence of Trisomy of 21 on the expression of IFN-a receptors on
peripheral blood mononuclear cells of individuals with DS
[25,26] and in ﬁbroblast cell lines derived from human skin of DS
individuals [24].Despite the involvement of IFNs in the immune response and
the relevance of the immune response to PD, to our knowledge
there is no information on the expression of IFN signaling pathway
genes in individuals with DS during periodontitis. In this study we
show a reduced expression of downstream activators of IFN signal-
ing in DS patients with periodontitis, suggesting that this inﬂam-
matory pathway does not play a role in increased destruction of
periodontal tissues observed in DS patients.2. Materials and methods
2.1. Subject population
All patients enrolled in the present study were also included in
a recent study of our group which investigated mRNA levels of the
interleukin-10 signaling pathway genes to reach potential inﬂu-
ence of DS in modulation of host immune response caused by peri-
odontitis [19]. This study was approved by the local Ethical
Committee (process number 79/04 – FOAr-UNESP). All patients
with DS and their parents as well as chromosomally normal (eu-
ploid) individuals were informed about the study and informed
consent forms were signed. A total of 150 patients with DS and
100 chromosomally normal patients were initially recruited into
the study. Their medical history was taken and they underwent a
clinical periodontal examination in the School of Dentistry of Ara-
raquara (UNESP) and in 12 of the Associations of Parents and
Friends of Disabled Patients (APAEs) of Araraquara and the sur-
rounding cities (Bocaina, Jaú, Ibitinga, Itápolis, Dourado, Taquarit-
inga, Matão, Jaboticabal, Ibaté, São Carlos and Guaíra) from
March 2005 to December 2007.
All DS patients were referred to a cardiologist before clinical
analysis. Patients diagnosed with cardiac abnormalities were pre-
scribed an appropriate antibiotic prophylaxis to avoid the risk of
complications such as endocarditis.
To be enrolled in the study, the participants were selected on a
three step process: (1) non-institutionalized DS adult subjects (i.e.,
older than 19 years, according to WHO [43]) with a karyotype of
simple 21st trisomy (mosaics were excluded) and chromosomally
normal (euploid) adult individuals. (2) None of the following exclu-
sion criteria: diabetes mellitus or any other chronic inﬂammatory
disease or infections; pregnancy or lactation; current smoker sta-
tus or cessation of smoking for less than 5 years; use systemic
and/or topical steroidal and non-steroidal anti-inﬂammatory drugs
or antibiotics during the last 3 months before the experimental
phase. (3) The subjects had to have areas with indication for oral
surgery treatment (tooth extractions and/or periodontal surgery)
to enable obtaining gingival biopsy.2.2. Clinical parameters
All subjects underwent an intra-oral clinical examination by a
single trained and calibrated examiner. For calibration, a total of
252 sites were randomly evaluated in six subjects (one quadrant
per patient). The examiner evaluated PPD on two occasions, 48 h
apart, and data were submitted to Student’s t-tests. This analysis
was repeated throughout the period of data collection because
the patient selection was spread over many months. Calibration
was made with the aim of standardizing the evaluation criteria
and was approved because evaluation differences between the
two periods were not statistically signiﬁcant (83% of sites showed
1 mm of maximum variation between tests; p > 0.05; kappa test).
Full-mouth clinical measurements (except for third molars) includ-
ing visible plaque index (VPI) [44]; gingival bleeding index (GBI)
[44]; bleeding on probing (BOP), probing pocket depth (PPD) and
clinic attachment loss (CAL) were conducted using a manual
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Chicago, IL, USA). Six sites per tooth were evaluated for PPD, BOP
and CAL (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual,
mid-lingual and disto-lingual). Patients were classiﬁed as peri-
odontally diseased when exhibiting more than three non-adjacent
sites with CAL and PPDP4 mm and BOP. Patients were classiﬁed
without periodontitis when exhibiting a maximum of three non-
adjacent sites with PPDP4 mm and 15% of sites with BOP [45].
Subjects were divided into the following groups based on their ge-
netic condition and periodontal status:
 DS+PD: Down syndrome individuals with periodontal disease
(n = 19).
 E+PD: Euploid individuals with periodontal disease (n = 20).
 EH: Euploid individuals periodontally healthy (n = 12).
2.3. Gingival tissue collection
During the surgical procedure, a gingival biopsy of about 3 mm3
was obtained from each individual. From individuals with peri-
odontitis, an area of inﬂamed gingiva with CAL and PPDP4 mm
was chosen, whereas from those without periodontitis, a non-
inﬂamed area of gingival tissue was selected. Biopsied gingival
specimens (containing epithelium and connective tissue) were
immediately immersed in a microtube containing 500 lL of RNA
extraction solution (Invitrogen, Carlsbad, CA, USA) and stored at
80 C until extraction of the total RNA.
2.4. RNA extraction and reverse transcription
Total RNA was extracted from each gingival tissue biopsy by
macerating the tissue with phenol and guanidine isothiocyanate
and following manufacturer’s (Invitrogen, Carlsbad, CA, USA)
instructions. Digestion of contaminating genomic DNA was per-
formed using RNAse-free DNAse (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. The quality of RNA
was assessed by agarose gel electrophoresis, and its concentration
and purity were assayed by measuring the A260/280 ratio using a
spectrophotometer (Biophotometer, Eppendorf, Germany) and the
ratio was always >1.8. At least 350 ng RNA was used for the reverseTable 1
Primer information: accession number of deposited mRNA sequences for the target gene,
Target gene Accession number Type Primer sequen
ACTB NM_001101.3 F 50 AAGCCACC
R 50 AATTTACAC
IFNA NM_000619 F 50 GAAACGAG
R 50 GCTGCTGG
IFNGR1 NM_000416 F 50 GGTCTGTG
R 50 CGGGACCA
IFNGR2 NM_005534 F 50 GGAAAAGG
R 50 AGCTCCGA
IFNA NM_002169 F 50 GAAGAATC
R 50 ATGGAGGA
IFNAR1 NM_000629 F 50 CACTTCTTC
R 50 ATTGCCTTA
IFNAR2 NM_207584 F 50 TCATATGAT
R 50 TGGTACAA
JAK1 NM_002227 F 50 GTCACAAC
R 50 CGGAGGGA
STAT1 NM_139266 F 50 GTGTTATG
R 50 AAGACCAG
IRF1 NM_002198 F 50 GCATGGCT
R 50 CTTGGGATtranscription (RT) reaction in a ﬁnal volume of 20 lL, using a
SuperScript III First Strand Synthesis Super Mix (Invitrogen, Carls-
band, CA, USA). The obtained cDNA was stored at 80 C until the
polymerase chain reaction (PCR) ampliﬁcations were carried out.
2.5. Quantitative real-time PCR (qPCR)
Expression of IFNG, IFNA and their receptors (IFNGR1, IFNGR2, IF-
NAR1 and IFNAR2), JAK-1, STAT-1 and IRF-1mRNA were determined
by quantitative PCR (qPCR) performed in a Real Time PCR System
(Applied Biosystems, Foster City, CA, USA) using the SYBR Green
chemistry for detection (Applied Biosystems, Warrington, UK).
Oligonucleotide primers for the target genes were designed
from sequences in the GenBank database using the Primer Express
3 software (Applied Biosystems, Foster City, CA, USA). The primer
sequences, the product region, the predicted amplicon sizes and
the annealing temperatures are depicted in Table 1. PCR reaction
conditions for all primers were optimized and all the reactions in-
cluded a melting curve to assess the formation of primer-dimers.
All qPCR reactions in a ﬁnal volume of 25 lL were assayed in
96-well optical plates (Applied Biosystems, Singapore, SG) using
the following cycling parameters: 50 C for 2 min and 95 C for
10 min; PCR cycling for 40 cycles at 95 C for 15 s, 60 C for
1 min and a dissociation cycle (95 C for 15 s, 60 C for 1 min,
95 C for 15 s and 60 C for 15 s). Negative controls with nucle-
ase-free water (Ambion, Life Technology, CA, USA) instead of cDNA
were performed for all reactions.
Calculations for determining the level of gene expression were
made by reference to the housekeeping gene, ACTB (b-Actin), in
the sample using the cycle threshold (Ct) method. The mean Ct val-
ues from duplicate measurements were used to calculate expres-
sion of the target gene, with normalization to the reference gene
using speciﬁc quantiﬁcation software Relative Quantiﬁcation
(ddCt) Study software (Applied Biosystems, Foster City, CA, USA).
2.6. Statistical analysis
The Shapiro–Wilk test was utilized to assess the normality of
the data. Thereafter, Mann–Whitney U tests were used for pairwise
comparisons between groups, as appropriate. Spearman’s correla-primer sequences, product size and annealing temperature (Ta).
ce Product amplicon size Ta (C)
CCACTTCTCTCTAA 30 88 58
GAAAGCAATGCTATCA 30
ATGACTTCGAAAAGC 30 113 58
CGACAGTTCA 30
AAGAGCCGTTGTC 30 142 58
CGTCAGGAATAT 30
AGCAAGAAGATGTTCT 30 93 58
TGGCTTGATCTC 30
TCTCCTTTCTCCTGCC 30 110 59
CAGAGATGGCTTG 30
ATGGTATGAGGTTGACT 30 96 59
TCTTCAGCTTCTAAATGT 30
TCGCCTGATTACACA 30 108 58
TGGAGTGGTTTTTTAATT 30
CTCTTTGCCCTGTAT 30 91 58
CATCTTGTCATCA 30
GGACCGCACCTT 30 107 58
CGGCCTCTGA 30
GGGACATCAAC 30 97 58
CTGGCTCCTTTTC 30
878 M.H. Tanaka et al. / Cytokine 60 (2012) 875–881tions (q) were used to investigate associations among the clinical
parameters and gene expression of the gingival biopsy of each
group. Statistical analysis was performed using Statistica 8.0 for
Windows. For all of the tests used, values of p < 0.05 were consid-
ered statistically signiﬁcant.3. Results
3.1. Demographic and clinical ﬁndings
Age, gender distribution and number of teeth were similar in all
individuals, indicating the homogeneity of these data in the total
sample (p > 0.05). Because the data distribution was not normal,
median (minimum and maximum) values are presented for DS+PD,
E+PD and EH, respectively (Table 2).
3.2. Gene expression analysis by RT-qPCR
The mRNA levels for each investigated gene after the normaliza-
tion by the b-Actin gene expression are shown in Fig. 1. Individuals
with DS+PD demonstrated signiﬁcantly lower expression of STAT1
(Fig. 1H) (p < 0.02) and IRF1 (Fig. 1I) (p < 0.01) in comparison with
E+PD. Considering the euploid individuals, the mRNA expression
levels of IFNGR1 (Fig. 1C), IFNGR2 (Fig. 1E), IFNAR1 (Fig. 1D), STAT1
(Fig. 1H) and IRF1 (Fig. 1I) was signiﬁcantly higher in the presence
of PD.
3.3. Correlation analysis of the clinical periodontal and gene expression
data
The correlation analysis among the clinical periodontal param-
eters of the gingival biopsied sites and gene expression is shown in
Table 3. DS+PD demonstrated a strong positive correlation be-
tween IFNA mRNA levels and PPDP4 mm (0.74). For E+PD, strong
negative correlation (0.74) were observed between CAL (mean)
and IFNGR2 mRNA levels. Regarding EH was observed strong neg-
ative correlation (0.84) between IFNAR2 and STAT1 mRNA levels
and both PPD (mean) and CAL (mean) indices.4. Discussion
Mechanisms responsible for the beginning and progression of
PD are not well understood in DS individuals. While the role of
the IFN-c and the IFN-a in PD have been investigated in euploid
individuals, to our knowledge, this is the ﬁrst study which assessed
the participation of these mediators and other important related
genes in the diseased tissue (gingival biopsies) from DS individuals
affected by PD, and also, compared with euploid individuals.Table 2
Demographic and clinical periodontal ﬁndings of the studied subjects.
Variables DS+PD E+PD EH
Gender (M/F) 14/5 9/11 3/9
Age 31.00 (22–48) 42.00 (21–66) 33.50 (20–49)
Number of teeth 23.00 (14–32) 24.50 (10–36) 29.00 (18–31)
BOP (%) 45.90 (25–100)a 45.00 (24–100)a 5.00 (0–11)b
PPD 6 3 mm (%) 61.00 (33–71)a 58.50 (22–61)a 80.00 (70–97)b
PPDP4 mm (%) 39.00 (10–40)a 41.50 (22–76)a 20.00 (6–22)b
CAL 6 3 mm (%) 58.00 (30–64)a 51.50 (22–55)a 80.00 (70–97)b
CALP 4 mm (%) 42.00 (9–47)a 48.50 (4–76)a 20.00 (6–22)b
Median (minimum–maximum). Different letters in rows mean statistically signiﬁ-
cant difference between groups (Mann–Whitney test). DS+PD: Down syndrome
individuals with periodontal disease; E+PD: Euploid individuals with periodontal
disease; EH: Euploid individuals periodontally healthy (modiﬁed from Cavalcante
et al. [19]).The importance of IFN-c in euploid individuals with PD has
been well documented [21,22,35,46,47]. Dutzan et al. [21] showed
that in gingival tissue of patients with chronic periodontitis the
IFNG gene expression at sites of active disease was 7.8 times great-
er than the expression at inactive sites (without PD). Surprisingly,
we did not ﬁnd a signiﬁcant difference on IFNG mRNA levels be-
tween euploid individuals with PD and periodontally healthy indi-
viduals. There was also no signiﬁcant difference in the IFNG
expression between individuals with DS with PD and euploid indi-
viduals with PD (Fig. 1A). This is particularly intriguing, since, all
the tissue samples from individuals with PD were harvested from
sites considered clinically active (PDP4 mm and presence of
bleeding on probing). Although unexpected, these results are con-
sistent with the reports of Roberts et al. [48] and Bickel et al. [20]
who also did not observe differences on IFNG mRNA levels in in-
ﬂamed and healthy gingival tissues. These authors hypothesized
that the lack of difference may be related with the low levels of
IFNG gene expression in these tissues. It is important to note that
we only assessed gene expression at the mRNA level and since IFNG
is also regulated at the post-transcriptional level and has a short
half-life [49,50] the protein levels may not correspond directly to
the mRNA.
Regarding the IFNGR1 and IFNGR2 gene expression, a previous
study showed that IFN-c receptor 2 was highly expressed in cell
culture of ﬁbroblasts derived from DS in comparison with control
ﬁbroblast cells, but not the IFN-c receptor 1 [24]. In the present
study, euploid individuals with PD showed higher expression of
both IFNGR1 and IFNGR2 when compared with euploid individuals
without PD, and there was no difference in the expression of these
receptors between DS and euploid individuals both affected by PD.
These results indicate that PD is associated with an increased
expression of IFNGR1 and IFNGR2 in the affected tissues. Impor-
tantly, in spite of DS individuals having an extra copy of the IFNGR2
gene this did not result in increased expression of this gene in gin-
gival tissue of DS patients. On the other hand, it is tempting to
speculate on an increased activity of the IFN signaling pathway
in PD as a result of a higher sensitivity of the cells to interferons
due to the increased expression of their receptors, even without
modulation of IFNA and IFNG genes. This hypothesis will be inves-
tigated in subsequent studies assessing expression of these recep-
tors at the protein level directly on immune cells.
Controversial results have been reported on the differential
expression of IFN-a in patients with and without PD [27–
29,51,52]. Prabhu et al. [51] found IFNA mRNA levels signiﬁcantly
higher in gingival tissue of patients with PD in comparison with
periodontally healthy individuals. In agreement, Wright et al.
[29] observed that IFN-a protein levels were twofold higher in
peripheral blood of patients with periodontitis in comparison with
periodontally healthy patients (p = 0.0045), and periodontal treat-
ment reduced IFN-a concentration to levels similar to those of
periodontally healthy individuals (p = 0.603). Kajita et al. [52]
found that the IFNA mRNA expression was higher in patients with
chronic periodontitis compared to patients with gingivitis
(p = 0.033), although low expression levels were detected in both
groups. Conversely, a study conducted by Mathur et al. [27]
showed no difference in the IFN-a protein concentration in gingi-
val crevicular ﬂuid of patients with chronic periodontitis in com-
parison to healthy subjects. Similar results regarding to IFNA
protein levels were observed by Wolff et al. [28] in gingival crevic-
ular ﬂuid. We did not ﬁnd a signiﬁcant difference on IFNA mRNA
expression in individuals with PD (independently of the presence
of DS) compared to individuals without PD (Fig. 1B). However, in
the DS with PD there was a positive signiﬁcant correlation between
IFNA mRNA levels and the PPDP4 mm (0.74), which may be re-
lated to a higher sensitivity of the responsive cells associated with
a higher expression of the receptors.
Fig. 1. Expression of IFNG, IFNGR1, IFNGR2, IFNA, IFNAR1, IFNAR2, JAK1, STAT1 and IRF1 in all individuals. Differences in the comparisons of gene expression between the DS+PD
and E+PD, and between E+PD and EH were evaluated by Mann–Whitney U test (p < 0.03).
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Table 3
Correlation coefﬁcients between the clinical data and mRNA expression levels for
IFNG, IFNGR1, IFNGR2, IFNA, IFNAR1, IFNAR2, JAK1, STAT1 and IRF1 in all individuals.
BOP
(%)
PPD
(mean)
CAL
(mean)
PPDP4 mm CALP 4 mm
DS+PD
IFNG 0.15 0.39 0.52 0.24 0.48
IFNGR1 0.09 0.42 0.44 0.29 0.40
IFNGR2 0.03 0.19 0.25 0.26 0.32
IFNA 0.30 0.60 0.39 0.74 0.41
IFNAR1 0.01 0.19 0.17 0.06 0.31
IFNAR2 0.08 0.33 0.02 0.53 0.02
JAK1 0.12 0.40 0.42 0.39 0.42
STAT1 0.02 0.09 0.46 0.09 0.58
IRF1 0.08 0.34 0.01 0.29 0.14
IFNG 0.21 0.01 0.33 0.00 0.11
IFNGR1 0.12 0.30 0.16 0.07 0.13
IFNGR2 0.03 0.42 0.74 0.03 0.15
IFNA 0.19 0.00 0.03 0.15 0.00
E+PD
IFNAR1 0.25 0.19 0.15 0.23 0.15
IFNAR2 0.04 0.38 0.18 0.10 0.34
JAK1 0.02 0.14 0.58 0.11 0.07
STAT1 0.01 0.11 0.43 0.10 0.00
IRF1 0.26 0.11 0.66 0.14 0.07
IFNG 0.15 0.35 0.35
IFNGR1 0.20 0.67 0.67
IFNGR2 0.37 0.49 0.49
IFNA 0.15 0.16 0.16
EH
IFNAR1 0.25 0.24 0.24
IFNAR2 0.13 0.84 0.84
JAK1 0.16 0.18 0.18
STAT1 0.16 0.84 0.84
IRF1 0.11 0.41 0.41
Statistically signiﬁcant values are presented in bold. DS+PD: Down syndrome
individuals with periodontal disease; E+PD: Euploid individuals with periodontal
disease; EH: Euploid individuals periodontally healthy.
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cated on chromosome 21 and there is evidence demonstrating
higher expression in the peripheral blood of individuals with DS
in comparison with euploid individuals [24,25,53]. However,
in vitro responsivity of PBMC of DS individuals to IFN-a is reduced,
which was associated with the increased prevalence of infectious
and malignant diseases in those individuals [25]. Expression of
IFN-a receptor 1 was higher in ﬁbroblasts cell lines from DS indi-
viduals in comparison with ﬁbroblasts cell lines from euploid indi-
viduals [24]. We did not ﬁnd signiﬁcant difference on IFNAR1
mRNA expression in gingival tissues affected by PD, both in DS
and euploid individuals (Fig. 1D). However, the IFNAR1 expres-
sion was signiﬁcantly higher in euploid individuals with PD com-
pared to individuals without PD (Fig. 1D). IFNAR2 gene
expression in the gingival tissues was not affected by PD or DS
(Fig. 1F). Therefore, even though IFN-a receptor genes are located
on chromosome 21, its expression was similar in DS and euploid
individuals.
The present study also investigated the expression of JAK1 and -
STAT1 genes, since these molecules are classical downstream tar-
gets of IFN-c and IFN-a signaling [54–56]. Gene expression
of JAK1 and STAT1 were previously demonstrated to be greatly
increased in response to stimulation of blood cells with either -
IFN-c or IFN-a [57]. In the Fig. 1G, we show that there were no
statistical differences in JAK1 expression in the gingival tissues,
regardless of the genetic and clinical conditions. On the other
hand, STAT1 expression was signiﬁcantly reduced (1.2-fold) in
DS with PD in comparison with euploid individuals with
PD (Fig. 1H). This ﬁnding appears to support the hypothesis of adeﬁciency in the immune response of DS individuals. This is sup-
port by the ﬁnding that PD was associated with increased expres-
sion of STAT1 mRNA in the gingival tissues of euploid patients.
However, in the same DS patients, we recently reported on the re-
duced expression of IL10 coupled with an increase of STAT3 and
reduction of SOCS3 genes, which rather interestingly suggests an
increased severity of inﬂammation [19]. In fact, low doses of
IFN-c cause an increased production of IL-6 by ﬁbroblasts from
DS patients [24]. STAT-3 is activated by IL-6 signaling, which we
reported in our previous study, as well as reduced expres-
sion of IL10 and SOCS3, the endogenous negative regulator of STAT3
[19] . This suggests a complex regulation of the immune response
in the periodontal microenvironment in DS patients, which may
present a shift to Th1-type responses (based on reduced IL10
mRNA and increased expression of STAT3, IFNGR1 and IFNGR2).
However, we cannot derive the status of activation of the
downstream signaling intermediates of IFN signaling directly from
their mRNA expression; and this will require assessment of the
phosphorylation status and subcellular localization in subsequent
studies.
Importantly, STAT1 gene is under direct transcriptional regula-
tion by IFNs, but it may also be regulated by IRF1 positive feedback
mechanisms, which further increase STAT1 gene expression [58–
60]. In agreement, it is interesting to note that there was a similar
pattern of gene expression of STAT1 and IRF1 genes among the
studied groups (Fig. 1H and I), which can be illustrated by the
strong positive correlation (q = 0.75) between STAT1 and IRF1 in DS
with PD (Supplemental data). Therefore, the reduced expression of
STAT1 in the gingival tissues of DS patients may be associated with
the reduced IRF1 mRNA levels that are also signiﬁcantly lower in
DS patients in comparison with euploid individuals with PD.
Therefore, taking into account the present results, we suppose that,
even DS individuals having an extra 21 chromosome that carries an
extra copy of IFNGR2, IFNAR1 and IFNAR2 genes, in the gingival tis-
sue affected by PD, the difference between them and euploid indi-
viduals regarding to the IFNs related genes resides on the
expression of the transcriptional factors STAT1 and IRF1.
Overall, the results of this study suggest that individuals with
DS exhibit a less efﬁcient interferon-mediated immune response a-
gainst microbial stimulus in the periodontal microenvironment.
This ﬁnding, coupled with previous information on increased
severity of inﬂammation in DS and higher prevalence of PD in these
patients suggests a complex regulation of the immune response in
the host-microbial interactions in the periodontal microenviron-
ment. In conclusion, the expression of STAT1 and IRF1 genes were
reduced in DS patients in comparison with euploids during the
same inﬂammatory stimulus of PD. This result corroborates the lit-
erature’s knowledge of the DS impaired immune response. In addi-
tion, this contributes to the observed increased prevalence and
severity of periodontitis in DS patients.Acknowledgments
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